News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma Appoints Nicklas Westerholm as New CEO

April 6, 2017

PledPharma AB
Company Announcement

PledPharma Appoints Nicklas Westerholm as New CEO

PledPharma announces today that Nicklas Westerholm has been appointed as new
Chief Executive Officer, effective June 16, 2017. 

Stockholm, 2017-04-06 08:00 CEST (GLOBE NEWSWIRE) -- 

The recruitment is aligned with the ambition of the Board of Directors to add
further resources and expertise to company management, ahead of the continued
clinical development and commercialization of the drug candidates PledOx® and

Nicklas Westerholm, b. 1976, has since 1995 been working in the AstraZeneca
Group in several global roles and different business areas, most recently as
Vice President Project & Portfolio Management, Cardiovascular and Metabolic
Diseases, Global Medicines Development Unit. Prior positions include roles as
Executive Officer and Vice President of Japan Operations, Director Investor
Relations, Head of Global API Supply and Head of Development Manufacture.
Nicklas Westerholm has studied analytical and organic chemistry at Stockholm
University, and Chemical Engineering at KTH Royal Institute of Technology. He
has also participated in educational programs at the University of Warwick,
INSEAD and Harvard Business School. 

"We are delighted to welcome Nicklas Westerholm as PledPharma’s new CEO. His
extensive experience and leadership skills will be important to strengthen the
organization and execute the continued clinical development and
commercialization of our drug candidates PledOx® and Aladote®," says Håkan
Åström, Chairman of PledPharma. 

"I am both humbled and excited by the appointment as CEO in PledPharma, and
look forward to lead and develop the company with the objective of making
PledOx® and Aladote® available for those patients who are at risk of severe
health impairment following chemotherapy or overdose of acetaminophen.
Chemotherapy induced nerve damage, like acetaminophen-induced liver failure,
are serious conditions lacking effective treatment. The market potential for
PledPharma’s drug candidates are significant, and consequently also the
opportunities to create value for the company’s shareholders," says Nicklas
Westerholm, incoming CEO. 

In conjunction with Nicklas Westerholm assuming his position on June 16, 2017,
the current CEO, Jacques Näsström, will transition to a leading position where
he will be continuously engaged in PledPharma’s research and development

For further information, please contact:

Håkan Åström, Chairman of the Board

Tel. +46 (0)70-374 72 13

Jacques Näsström, Chief Executive Officer

Tel. +46 (0)73-713 09 79

Nicklas Westerholm, incoming Chief Executive Officer

Tel. +46 (0)73-354 20 62

About PledPharma

PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company's most advanced project PledOx® is being developed to
reduce nerve damage associated with chemotherapy. A phase IIb study has been
conducted and will serve as the basis for the continued development. The drug
candidate Aladote® is being developed to reduce the risk of acute liver failure
associated with acetaminophen poisoning. 

PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the
company’s Certified Adviser (tel +46 8 463 80 00). For more information, see 

This information is information that PledPharma AB (publ) is obliged to make
public pursuant to the EU Market Abuse Regulation and the Securities Markets
Act. The information was submitted for publication, through the agency of the
contact person set out above, at CET 08:00 on April 6, 2017.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10